Company: Unity Biotechnology
Job title: Co-Founder & President
Ned co-founded UNITY in 2011 because he thought it was “simply the coolest biology he had ever seen.” Prior to that, Ned co-founded Syrrx (acquired by Takeda), Achaogen (AKAO), and Kythera Biopharmaceuticals (KYTH, acquired by Allergan) and the work of these companies ultimately gave rise to three FDA-approved medicines (NESINA, ZEMDRI, and KYBELLA). Ned builds companies because he sees company creation as a means to create technologies that change the world. Ned holds pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, aesthetic medicine, and cellular senescence. He has served on the board of directors of Kythera Biopharmaceuticals and the Buck Institute for Research on Aging and is a member of the board of trustees of the University of California Foundation. He holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard University.
Opening Keynote: Unity Biotechnologies’ Pipeline Progression: From Mice Models to First-in-Human Trials 9:00 am
Reverse the process of aging with drugs that target particular mechanisms of aging Examine how senescent cells from mice extends life and blunts numerous age associated diseases, including cardiovascular disease, kidney disease, lung diseases, cognitive decline and eye diseases Discuss new results and where we can go from thereRead more
day: Day One